
CAC2 Childhood Cancer Community News Digest (August 15-28)
Assorted News from the Last Two Weeks: The Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) for the treatment of children aged 1 year or

Assorted News from the Last Two Weeks: The Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) for the treatment of children aged 1 year or

Assorted News from the Last Week: Leukemia and Lymphoma Society’s (LLS) has launched its Dare to Dream Project as an extension of itself Children’s Initiative.

Assorted News from the Last Two Weeks: The CCDI Molecular Targets Platform is the National Cancer Institute’s instance of the Open Targets Platform, specific to

Assorted News from Last Week: The Biden administration has selected Monica Bertagnolli, a renowned surgical oncologist, as the next director of the National Cancer Institute.

Assorted News from Last Week: Researchers have identified the child cancer patients at greatest risk of developing life-threatening infections, in a crucial step towards the

Assorted News from Last Week: Three things to know if your child is diagnosed with cancer. CNN Correspondent Rene Marsh tells the story of her pediatric

Assorted News from Last Week: Childhood cancer survivors of certain racial and ethnic groups were prone to more hospitalizations for various conditions years down the

Survivorship Matters Blog By CAC2 Member Mary Beth Collins, PREP4Gold During his teens, my neuroblastoma survivor Joshua was struggling in every way a person could

Assorted News from Last Week: Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and